Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.63 |
| ▸ | POLB | P06746 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MASP2 | O00187 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29543730 | 0.84 | KMT2A (0.70) | NPSR1ALDH1A1KDM4EPOLBSMN1; SMN2 | |
| SCHEMBL111479 | 0.84 | KMT2A (0.70) | NPSR1ALDH1A1KDM4EPOLBSMN1; SMN2 | |
| Phenol SCHEMBL28121926 | 0.80 | KMT2A (0.64) | ALDH1A1KDM4EPOLBSMN1; SMN2ABCC1 | |
| SCHEMBL5129490 | 0.79 | KDM4E (0.63) | ALDH1A1KDM4EPOLBABCC1KMT2A | |
| SCHEMBL10035491 | 0.78 | KMT2A (0.71) | ALDH1A1KDM4EPOLBSMN1; SMN2ABCC1 | |
| SCHEMBL31212658 | 0.76 | CA1 (0.71) | ALDH1A1KDM4EPOLBSMN1; SMN2KMT2A | |
| SCHEMBL5455412 | 0.76 | CA1 (0.71) | ALDH1A1KDM4EPOLBSMN1; SMN2KMT2A | |
| SCHEMBL3627546 | 0.75 | MASP2 (0.62) | ALDH1A1KDM4EPOLBABCC1KMT2A | |
| SCHEMBL14906959 | 0.75 | MASP2 (0.67) | ALDH1A1KDM4EPOLBABCC1KMT2A | |
| SCHEMBL9532980 | 0.75 | CYP2C9 (0.69) | ALDH1A1KDM4EPOLBSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138356-B2 | Chemical inhibitors of inhibitors of differentiation | Angiogeney, Inc. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090226422-A1 | Chemical Inhibitors of Inhibitors of Differentiation | ANGIOGENEX | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226422-A1 | Chemical Inhibitors of Inhibitors of Differentiation | BRAF, MAPK1, RAF1 | NPSR1 3006/4885ALDH1A1 1860/4885KDM4E 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.